The Ying lab focuses on establishing the causal relationship between cancer lesions, environmental cues, tissue damaging stresses and epithelial cell fate choice in homeostasis, malignant growth and tissue regeneration. In the past few years, we build up the know-hows to rapidly test single or pooled gene function using embryonic transduction of oral and breast epithelia, and directly observe cell fate choice using intra-vital as well as whole mount 3D imaging. With these cutting-edge technologies, we discovered that oncogene induced differentiation creates a barrier to clonal expansion that acts as a dominate tumor suppressive mechanism. In mammary epithelium, we characterized the growth dynamics of its early progenitors using barcoded lineage tracing, and established that every mouse mammary gland originates form a defined number of ectodermal progenitors that will give rise to epithelial clones of equal expansion potential. Based on this insight, we developed a genetic screen platform that that is capable to test up to ~1200 individual genetic conditions in intact mammary glands of one single mouse. Recently, the Ying lab is building up the capability of studying the high-dimensional combinatorial effect of genetic lesions/signaling pathways, which closely resembles the mode of action of heterogeneous cancer genomes, using our next-generation lentivirus-based single cell barcoding systems.
Lab website: https://labs.icahn.mssm.edu/yinglab/
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Ying did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.